| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | SELL | SELL | SELL | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 9.50▼ | 9.48▼ | 9.48▼ | 9.78▼ | 10.92▼ |
| MA10 | 9.55▼ | 9.36▲ | 9.36▲ | 10.01▼ | 9.96▼ |
| MA20 | 9.54▼ | 9.62▼ | 9.68▼ | 11.17▼ | 10.89▼ |
| MA50 | 9.93▼ | 10.18▼ | 10.18▼ | 9.78▼ | 14.44▼ |
| MA100 | 10.31▼ | 10.97▼ | 11.14▼ | 11.46▼ | 7.82▲ |
| MA200 | 11.27▼ | 10.41▼ | 10.34▼ | 15.43▼ | 5.62▲ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.035▲ | 0.026▲ | 0.021▲ | -0.298▼ | 0.038▲ |
| RSI | 44.485▼ | 43.723▼ | 43.161▼ | 40.752▼ | 41.004▼ |
| STOCH | 51.362 | 61.105 | 58.931 | 17.847▼ | 57.475 |
| WILL %R | -42.795 | -54.035 | -54.035 | -92.186▼ | -71.870 |
| CCI | -3.869 | -7.163 | -20.074 | -108.923▼ | -35.005 |
|
Monday, September 28, 2026 04:46 AM
Palatin Technologies (NASDAQ:PTN) reports $13.2 million fiscal 2026 revenue and updates MC4R obesity drug development plans.
|
|
Monday, September 28, 2026 04:46 AM
Palatin Technologies (NASDAQ:PTN) reports $13.2 million fiscal 2026 revenue and updates MC4R obesity drug development plans.
|
|
Monday, September 28, 2026 04:30 AM
Palatin Technologies, Inc. (Nasdaq: PTN), a biopharmaceutical company developing medicines that target the melanocortin receptor ("MCR") system, today reported financial results for the fiscal year ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 29/09/26 | 9.54 | 9.69 | 9.04 | 9.12 | 32,834 |
| 28/09/26 | 9.86 | 10.09 | 8.725 | 9.58 | 39,008 |
| 25/09/26 | 9.85 | 10.35 | 9.50 | 10.095 | 22,381 |
| 24/09/26 | 10.12 | 10.12 | 9.60 | 9.83 | 26,519 |
| 23/09/26 | 10.79 | 10.79 | 9.81 | 10.27 | 41,210 |
| 22/09/26 | 10.66 | 10.705 | 10.00 | 10.27 | 41,661 |
| 21/09/26 | 11.03 | 11.73 | 10.22 | 10.22 | 57,774 |
| 18/09/26 | 10.37 | 11.05 | 10.27 | 10.86 | 51,558 |
| 17/09/26 | 9.51 | 10.64 | 9.50 | 10.43 | 34,201 |
| 16/09/26 | 10.94 | 11.21 | 9.42 | 9.46 | 137,400 |
|
|
||||
|
|
||||
|
|